enGene Holdings Inc. (NASDAQ:ENGN) Given Consensus Recommendation of “Buy” by Brokerages

Shares of enGene Holdings Inc. (NASDAQ:ENGN) have received a consensus recommendation of “Buy” from the ten analysts that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $25.89.

Several research analysts recently commented on the stock. HC Wainwright began coverage on shares of enGene in a research note on Monday, December 23rd. They set a “buy” rating and a $25.00 price objective for the company. Citizens Jmp raised enGene to a “strong-buy” rating in a research report on Monday, November 18th. UBS Group cut enGene from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $34.00 to $7.00 in a research report on Friday, February 14th. Piper Sandler began coverage on enGene in a research note on Tuesday, February 18th. They issued an “overweight” rating and a $26.00 price target for the company. Finally, Raymond James began coverage on enGene in a research note on Wednesday, November 27th. They set an “outperform” rating and a $23.00 price target on the stock.

enGene Stock Up 2.0 %

Shares of NASDAQ ENGN opened at $6.24 on Wednesday. The stock has a market capitalization of $276.07 million, a PE ratio of -10.76 and a beta of -0.65. The company has a current ratio of 16.87, a quick ratio of 16.87 and a debt-to-equity ratio of 0.08. enGene has a 12-month low of $4.42 and a 12-month high of $18.40. The stock’s fifty day simple moving average is $6.77 and its two-hundred day simple moving average is $7.19.

enGene (NASDAQ:ENGN) last posted its earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.06. As a group, analysts expect that enGene will post -1.56 EPS for the current fiscal year.

Hedge Funds Weigh In On enGene

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Fcpm Iii Services B.V. boosted its holdings in shares of enGene by 11.0% in the 4th quarter. Fcpm Iii Services B.V. now owns 9,632,561 shares of the company’s stock valued at $64,057,000 after acquiring an additional 954,610 shares during the last quarter. VR Adviser LLC lifted its position in enGene by 41.5% during the fourth quarter. VR Adviser LLC now owns 5,046,414 shares of the company’s stock valued at $33,559,000 after purchasing an additional 1,480,573 shares during the period. Deep Track Capital LP lifted its position in enGene by 74.8% during the fourth quarter. Deep Track Capital LP now owns 4,557,575 shares of the company’s stock valued at $30,308,000 after purchasing an additional 1,949,942 shares during the period. Blue Owl Capital Holdings LP grew its position in enGene by 3.3% during the 4th quarter. Blue Owl Capital Holdings LP now owns 3,159,975 shares of the company’s stock worth $21,014,000 after purchasing an additional 101,006 shares during the period. Finally, Point72 Asset Management L.P. raised its stake in shares of enGene by 84.7% during the 4th quarter. Point72 Asset Management L.P. now owns 1,224,797 shares of the company’s stock valued at $8,145,000 after buying an additional 561,797 shares during the last quarter. Institutional investors and hedge funds own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.